Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
olaparibp, embro · 1 trial · 1 indication
Progression free survival at 36 month according to Response Evaluation Criteria in Solid tumors RECIST 1.1
| Arm | Type | Description |
|---|---|---|
| Carbo/taxol/pembro followed by maintenance of olaparib/pembro post-surgery | EXPERIMENTAL | neoadjuvant carbo/taxol/pembro followed by maintenance olaparib/pembro post- surgery |
| Name | Type | Description |
|---|---|---|
| Carboplatin | DRUG | neoadjuvant treatment , followed by surgery, then maintenance chemotherapy |
| olaparibp, embro | DRUG | maintenance chemotherapy : olaparib, pembro |
Inclusion Criteria: * Participants are eligible to be included in the study only if all of the following criteria apply: 1. Participant has histologically confirmed FIGO Stage III or Stage IV EOC (high-grade predominantly serous, endometrioid, carcinosarcoma, mixed Mullerian with high grade sero...
Top 20 of 59 competitors
Olaparibp, embro is an investigational small molecule being studied for the treatment of ovarian cancer. It is currently in a Phase 2 clinical trial for patients with newly diagnosed Stage III/IV ovarian cancer, where it is evaluated as a maintenance therapy following neoadjuvant treatment with carboplatin, paclitaxel, and pembrolizumab.
Olaparibp, embro is a small molecule oncology drug. Its specific molecular target is not disclosed in the available information. The ongoing Phase 2 trial is biomarker-selected, indicating that patient eligibility may be based on specific genetic or molecular markers, though the exact target is not specified.
Olaparibp, embro is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting a Phase 2 clinical trial to evaluate the drug in ovarian cancer.
Olaparibp, embro is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing trial is a single-arm, open-label study, meaning it is not randomized or double-blinded, and it does not use a control group.
Olaparibp, embro is being studied in one active Phase 2 clinical trial with the identifier NCT05952453. This trial is recruiting female patients aged 18 years and older in the United States with newly diagnosed Stage III/IV ovarian cancer. The study plans to enroll 20 participants and is currently in the recruiting phase.
Olaparibp, embro is a distinct drug candidate from olaparib, which is an approved PARP inhibitor. While both are small molecules used in ovarian cancer, olaparibp, embro is a separate investigational compound being developed by Merck & Company, Inc. The available information does not indicate that they are the same drug.